[Direct-to-consumer genetic tests in the consulting room]

Area of Science:

• Genomics
• Personalized Healthcare
• Bioethics

Background:

• Direct-to-consumer genetic tests (DTC-GT) are increasingly prevalent due to advances in genome technology and personalized medicine.
• DTC-GT encompass both non-medical traits and medical risk assessments for conditions like Alzheimer's and cancer.

Purpose of the Study:

• To evaluate the clinical validity, analytical validity, and ethical implications of DTC-GT.
• To examine the regulatory landscape for DTC-GT within Dutch law.
• To identify factors influencing the clinical utility of DTC-GT.

Main Methods:

• Review of current literature on DTC-GT analytical and clinical validity.
• Ethical analysis of potential benefits versus risks associated with DTC-GT.
• Assessment of existing Dutch legislation concerning genetic testing.

Main Results:

• Low clinical and often unknown analytical validity of DTC-GT hinders accurate interpretation of health risks.
• Ethical concerns include privacy, inadequate information, misinterpretation, over-diagnosis, and increased healthcare costs.
• Regulatory ambiguity exists regarding the authorization of DTC-GT under Dutch law.

Conclusions:

• Enhancing the clinical utility of DTC-GT necessitates clearer legal and regulatory frameworks.
• Improved information and guidance from DTC-GT providers are crucial for consumers.
• Integrating DTC-GT into healthcare professional education is essential for responsible implementation.